ReviewFrontiers in psychiatry2021
BDNF as a Biomarker of Cognition in Schizophrenia/Psychosis: An Updated Review.
Review in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 3 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Exploration of current situation of psychotropic drugs research and development in China based on drug clinical trials.Frontiers in psychiatry · 2025Pooled it
- Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Schizophrenia and Bipolar Disorder: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Pooled it
- Effect of Whole-Body Vibration on Serum Levels of Brain Derived Neurotrophic Factor and Cortisol in Young, Healthy Women.International journal of environmental research and public health · 2022Trial
- Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial.Neural plasticity · 2021Trial
- Additive Effects of Cognitive Remediation and Physical Exercise in Patients with Schizophrenia: Cognitive Improvements.Brain sciences · 2026Review
- Human biomarker navigator.iMeta · 2026Review
- Could brain-derived neurotrophic factor, irisin, and peroxisome proliferator-activated receptor-gamma be a pathway in cognitive impairment in schizophrenia?BMC psychiatry · 2026Article
- Article
- Machine learning helps predict early onset psychosis with serum protein biomarkers, neuropsychometry, and clinicodemographic data.Scientific reports · 2025Article
- Effects of a Long-Term Exercise Training Program on the Functional Capacity and Health-Related Quality of Life in Inpatients with Psychotic Disorders: A Randomized Controlled Trial.Journal of functional morphology and kinesiology · 2025Article
- The efficacy and safety of risperidone combined with modified electroconvulsive therapy in the treatment of schizophrenia.Pakistan journal of medical sciences · 2025Article
- Alterations in the plasma concentrations of BDNF, proBDNF, and MMP-9 in patients with schizophrenia.European journal of medical research · 2025Article
- Peripheral BDNF Levels in Individuals at Ultra-High Risk for Psychosis: A Systematic Review.Brain sciences · 2025Review
- Neuropsychological profiles in first-episodes psychosis and their relationship with clinical, metacognition and social cognition variables.European archives of psychiatry and clinical neuroscience · 2025Article
- NGF-β and BDNF levels are altered in male patients with chronic schizophrenia: effects on clinical symptoms.BMC psychiatry · 2025Article
- Current Strategies and Future Directions of Wearable Biosensors for Measuring Stress Biochemical Markers for Neuropsychiatric Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Plant-derived polyphenolic compounds for managing schizophrenia: mechanisms and therapeutic potential.Frontiers in pharmacology · 2025Review
- Latent classes of mental health disorders and their associations with polymorphisms of 5HTTLPR and BDNF in a Chilean primary care population.Global mental health (Cambridge, England) · 2025Article
- The Role of Neuroglia in the Development and Progression of Schizophrenia.Biomolecules · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain Derived Neurotrophic Factor (BDNF) has been linked to cognitive symptoms of schizophrenia, which has been documented in previous reviews by several authors. However, a trend has recently emerged in this field moving from studying schizophrenia as a disease to studying psychosis as a group. This review article focuses on recent BDNF studies in relation to cognition in human subjects during different stages of the psychotic process, including subjects at high risk of developing psychosis, patients at their first episode of psychosis, and patients with chronic schizophrenia. We aim to provide an update of BDNF as a biomarker of cognitive function on human subjects with schizophrenia or earlier stages of psychosis, covering new trends, controversies, current research gaps, and suggest potential future developments in the field. We found that most of current research regarding BDNF and cognitive symptoms in psychosis is done around schizophrenia as a disease. Therefore, it is necessary to expand the study of the relationship between BDNF and cognitive symptoms to psychotic illnesses of different stages and origins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.